Universities Innovate, Big Pharma Develops: Public and philanthropic funding crucial to treat cancer

As France 24 marks World Cancer Day, François Picard welcomes Lars Henning Milman Engelholm, Associate Professor and Group Leader at the Finsen Laboratory at the University of Copenhagen. From his lab in Copenhagen, Professor Engelholm describes a seismic shift underway in pancreatic cancer research, the result of a decade-long commitment to the steady evolution of translational science. At the heart of this shift are antibody-drug conjugates (ADCs): highly targeted therapies designed to reach what conventional treatments cannot.